Founded by Dr Mark Kotter and Florian Schuster, bit.bio is an award-winning human synthetic biology enterprise.
bit.bio’s mission is to code cells for health. To do so, we apply the principles of computation to biology. Our current focus is to develop a scalable technology platform capable of producing consistent batches of every human cell.
To achieve our goals, we have assembled a team of pioneers in stem cells, cellular reprogramming, mathematical modelling, and cell therapy.
As biology transitions to engineering, we have the potential to unlock a new generation of medicine: we will enable research and drug discovery to move on from inappropriate models and work with the cells that actually are affected by human disease. A scalable platform of consistent cells will also be the basis for a new generation of cell and tissue therapies.
Mark is a stem cell biologist and neurosurgeon at the University of Cambridge. By combining synthetic and stem cell biology, his team has developed a benchmark technology for the efficient and consistent production of human cells for use in research, drug development, and cell therapy. He is the founder of bit.bio and co-founder of the cultured meat startup Meatable.
Florian is an active entrepreneur and investor. He is the co-founder and CCO at bit.bio. Previously, he was CFO & Head of Strategic Partnerships for Tessa Therapeutics, a clinical-stage cell therapy company. Florian is a former investment banker, a graduate of the Stanford School of Engineering, and an alumnus of Harvard Business School.
Kathryn has over 25 years experience in early and late drug development across multiple indications and platforms. She was partner at Takeda Ventures, Inc. and Head of Oncology Cell Therapy Development at Takeda Pharmaceuticals where she built capabilities and oversaw a cutting edge oncology cell therapy portfolio. Prior to that, she held several roles at Sanofi Genzyme and built a two decade career at Hoffman – La Roche, Roche Molecular Systems, Eli Lilly and Syndax, contributing to the approval of 6 new cancer therapies and expansion of multiple indications.
Ramy is a leading immuno-oncology clinician who has helped to develop some of the breakthrough therapies in this field. Ramy has served as the Vice President of Clinical Development for Immuno-oncology at AstraZeneca, and as a member of the Bristol-Myers Squibb Immuno-oncology program. Ramy also sits on the board at the Parker Institute for Cancer Immunotherapy.
Paul is a serial entrepreneur and scientist with over thirty years of experience in the biotech and pharma sectors. Most recently, he was the commercial founder and President of Horizon Discovery Group, and founder of CellRx Limited, a growth factors company serving the biopharmaceutical sector. Paul holds a PhD in Biotechnology from the University of Cambridge.
John is a leading cancer immunologist with over 20 years of experience in immunotherapy. He is focused on clinical translation and a world-renowned subject matter expert on building cell therapy manufacturing, clinical and regulatory capability. John serves as director for the IMPACT Program, a multi-disciplinary national initiative for Singapore. He is also Chief Scientific Officer at the Parker Institute for Cancer Immunotherapy and an associate professor at the National University of Singapore and an adjunct associate professor of Immunology at Baylor University.
Dr Hermann Hauser is a serial entrepreneur and co-founder of Amadeus Capital Partners where he invested in CSR, Solexa, Icera, Xmos and Graphcore. Solexa created the dominant gene-sequencing technology now sold by Illumina. He has wide experience in developing and financing companies in the ICT and life science sector. He is a founder of Acorn Computers which created the ARM processor and helped spin it out with Apple into an independent company. He is vice-chair of the European Innovation Council, the €10bn deep tech fund of Horizon Europe.
Sir Gregory Winter is a Nobel prize winning scientist who invented technologies for making therapeutic monoclonal antibodies, and was directly involved in their industrial development, notably through the start up company Cambridge Antibody Technology Ltd. His inventions underpin many of the therapeutic antibodies in development and on the market, including blockbuster drugs such as Humira, Herceptin, Avastin and Keytruda.
Alan S. Roemer, MBA, MPH is an entrepreneurial life sciences executive and board member who has launched three multi-billion dollar biotechnology companies, raised over $1.75 billion in private and public capital, and consummated five IPOs. His senior leadership experience in development-stage biotechnology companies includes finance, accounting, business development, operations & administration, human resources, legal, information technology, facilities, corporate communications, and investor relations.
Roger is a pioneer and thought leader in the field of human stem cell biology. His lab was the first to isolate pluripotent epiblast stem cells from the epiblast layer of the developing mammalian embryo. In addition, he developed one of the first cellular reprogramming protocols. Roger was co-founder of the Cambridge Stem Cell Institute. His lab is currently focused on differentiation of pluripotent stem cells, with potential applications for drug discovery, toxicity testing and cell therapies.
Marius’ seminal 2010 paper in Nature demonstrating direct conversion of fibroblasts into neurons has sparked a widespread interest in cell reprogramming. He is the co-director of the Stanford Stem Cell Institute. His lab uses cellular reprogramming to understand how neurons are induced, and how they mature and maintain their identity.
Marie-Claire is a leading international expert in sustainability, law and public policy. She is an award-winning expert jurist, executive and professor of law and governance on sustainable development. She also serves as Senior Director of the global Centre for International Sustainable Development Law (CISDL), advising the United Nations and key countries, also leading purpose-led companies on ethics and the UN Sustainable Development Goals.